FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD

Disclosures

January 11, 2018

In This Article

Bavencio (avelumab)

Indication:

Metastatic Merkel cell carcinoma (MCC) in adults and pediatric patients aged >12 years. Also indicated for advanced urothelial carcinoma (UC) in patients who have disease progression with platinum-based chemotherapy.

Mechanism:

Anti-PD-L1 IgG1 monoclonal antibody. Binding of PD-L1 to the PD-1 found on T cells and antigen-presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production.

Dosage:

10 mg/kg IV every 2 weeks. Continued until disease progression or unacceptable toxicity.

Approval:

Approval for MCC was based on the JAVELIN Merkel 200 open-label, single-arm, multicenter study in 88 patients with histologically confirmed metastatic MCC. Overall response rate (ORR) was 33%, partial response was 22%, and complete response was 11%. Approval for UC was based on the JAVELIN solid tumor trial. An ORR of 16.1% was observed in 161 patients with a follow-up >6 months.

References:

Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-85.

Apolo AB, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017 Apr 4.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....